Table 2

Development of drugs for IMIDs that target Janus kinases (JAKs). Development status based on http://adisinsight.springer.com, accessed 30 May 2017. AS, ankylosing spondylitis; CD, Crohn’s disease; IMID, immune-mediated inflammatory diseases; JIA, juvenile idiopathic arthritis; P-I, phase I clinical trial; P-II, phase II clinical trial; P-III, phase III clinical trial; SLE, systemic lupus erythematosus; Syk, spleen tyrosine kinase; TYK2, tyrosine kinase 2; UC, ulcerative colitis. *Baricitinib approved by the European Medicines Agency, although rejected by the Food and Drug Administration (April 2017).

DrugJAK targetsDeveloperPsoriasisPsAASRAIBDOther indications
First-generation pan-JAK inhibitors
Tofacitinib
[CP-690550, tasocitinib]
(Xeljanz, Jaquinus)
JAK1, JAK2, JAK3, (TYK2)PfizerP-III
(oral and topical)
SubmittedDiscontinuedMarketedP-III (UC)JIA (P-III)
Atopic dermatitis (P-II) Dermatomyositis (P-I)
SLE (P-I)
Ruxolitinib
[INC-424, INCB-18424]
(Jakafi, Jakavi)
JAK1, JAK2Novartis, IncyteP-II
(topical)
DiscontinuedPolycythaemia rubra vera (marketed)
Myelofibrosis (marketed)
Graft-versus-host disease (P-III)
Various other myeloproliferative disorders (P-II/P-III)
Vitiligo (topical, P-II)
Alopecia areata (topical and oral, P-II)
Baricitinib
[INCB-28050, LY-3009104]
(Olumiant)
JAK1, JAK2Eli Lilly, IncyteDiscontinuedP-IIIMarketed*SLE (P-II)
Atopic dermatitis (P-II)
Peficitinib
[ASP-015K, JNJ-54781532]
JAK1, JAK2, JAK3, TYK2Astellas PharmaDiscontinuedP-IIIDiscontinued (UC)
Second-generation selective JAK inhibitors
Filgotinib
[G-146034, GLPG-0634, GS-6034]
JAK1Galapagos NV, Gilead SciencesP-IIP-IIP-IIIP-III
(UC and CD)
Sjogren’s syndrome (P-II)
Cutaneous lupus (P-II)
Upadacitinib
[ABT494]
JAK1AbbVieP-IIIP-IIIP-III (UC)
P-II (CD)
Atopic dermatitis (P-II)
Solcitinib
[G154578, GLPG-0778, GSK-2586184]
JAK1GlaxoSmithKlineDiscontinuedDiscontinued (UC)SLE (discontinued)
Itacitinib
[INCB-039110]
JAK1AstraZeneca, IncyteDiscontinuedDiscontinuedGraft-versus-host disease (P-II)
Hodgkin’s lymphoma (P-II)
Non-small cell lung cancer (P-II)
Decernotinib
[Adelatinib, VRT-831509, VX-509]
JAK3Vertex PharmaceuticalsDiscontinued
R333JAK3, SykRigel PharmaceuticalsCutaneous lupus (discontinued)